Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2023 - nature.com
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
DM Cordas dos Santos, T Tix, R Shouval… - Nature medicine, 2024 - nature.com
Although chimeric antigen receptor (CAR) T cell therapy represents a transformative
immunotherapy, it is also associated with distinct toxicities that contribute to morbidity and …
immunotherapy, it is also associated with distinct toxicities that contribute to morbidity and …
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell …
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell …
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients
Purpose: Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for
hematologic malignancies, but patients can develop long-term adverse events, including …
hematologic malignancies, but patients can develop long-term adverse events, including …
The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following …
Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel)
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …
Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell …
G Iacoboni, V Navarro, AÁ Martín-López… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell
lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells …
lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells …
High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of …
O Hermine, L Jiang, J Walewski, A Bosly… - Journal of clinical …, 2023 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
N Jain, M Mamgain, SM Chowdhury, U Jindal… - Journal of Hematology & …, 2023 - Springer
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all
NHLs and characterized by overexpression of cyclin D1. The last decade has seen the …
NHLs and characterized by overexpression of cyclin D1. The last decade has seen the …
Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
PA Thompson, CS Tam - Blood, The Journal of the American …, 2023 - ashpublications.org
Patients with lymphoproliferative disorders such as chronic lymphocytic leukemia and
mantle cell lymphoma (MCL) who are resistant to covalent Bruton tyrosine kinase inhibitors …
mantle cell lymphoma (MCL) who are resistant to covalent Bruton tyrosine kinase inhibitors …